CD172a (SIRPα) Antibodies: Pioneering Macrophage-Directed Tumor Immunotherapy

Concept

Tumor immunotherapy has expanded beyond T cell-focused strategies to harness the innate immune system, with the CD47-SIRPα axis emerging as a critical target for reactivating macrophage-mediated anti-tumor immunity. Signal Regulatory Protein α (SIRPα), also known as CD172a, is an immunosuppressive receptor predominantly expressed on myeloid cells—including macrophages and dendritic cells. Its interaction with CD47, a widely expressed "don’t eat me" ligand on tumor cells, transmits inhibitory signals that block phagocytosis, enabling tumors to evade immune clearance. Unlike CD47-targeting therapies (which carry risks of off-target effects on normal cells like red blood cells), CD172a (SIRPα) antibodies offer enhanced cellular specificity by acting exclusively on myeloid effector cells. As a global leader in life science reagents, ANT BIO PTE. LTD. delivers cutting-edge solutions via its Starter sub-brand (flagship antibodies)—a portfolio of highly specific CD172a (SIRPα) antibodies optimized for mechanism research, preclinical validation, and drug development. All products are rigorously validated for specificity, functional activity, and batch consistency, serving as gold-standard tools for immunologists, oncology researchers, and biopharmaceutical developers.

Research Frontiers

CD172a (SIRPα) research is at the forefront of innate immune-focused immunotherapy, driving breakthroughs in macrophage activation, combination therapy, and preclinical model validation. ANT BIO PTE. LTD.’s specialized antibodies enable transformative discoveries in key high-impact frontiers:

1. Synergistic combination immunotherapies: Investigating how CD172a antibody-mediated checkpoint blockade synergizes with tumor antigen-targeting antibodies (e.g., anti-CD20), immune checkpoint inhibitors (e.g., anti-PD-1), or chemotherapy to enhance antibody-dependent cellular phagocytosis (ADCP) and anti-tumor efficacy.
2. Humanized model validation: Using CD172a antibodies to characterize humanized SIRPα (hSIRPA) mouse models, ensuring accurate preclinical evaluation of human-specific SIRPα-targeted therapies.
3. Biomarker discovery: Identifying CD172a expression levels or macrophage activation states (via antibody-based detection) as predictive biomarkers for response to SIRPα-targeted therapies.
4. Novel antibody engineering: Developing bispecific CD172a antibodies that co-target tumor antigens, enhancing macrophage recruitment and phagocytosis at the tumor site.
5. Solid tumor penetration: Optimizing CD172a antibody formulations or delivery systems to overcome tumor microenvironment barriers and activate macrophages in solid tumors.
6. SIRPα subtype-specific targeting: Exploring subtype-specific CD172a antibodies to address functional differences in SIRPα isoforms across tumor types and patient populations.
7. Beyond oncology: Extending CD172a antibody applications to autoimmune diseases and infectious diseases, where dysregulated CD47-SIRPα signaling contributes to pathology.

Research Significance

CD172a (SIRPα) antibodies are indispensable for advancing macrophage-directed immunotherapy and expanding the scope of cancer treatment, with far-reaching implications for preclinical research and clinical translation. ANT BIO PTE. LTD.’s high-performance reagents amplify the scientific and translational impact of this work:

1. Unlocking innate anti-tumor immunity: CD172a antibodies block the CD47-SIRPα axis, reactivating macrophages to phagocytose tumor cells—addressing an unmet need for patients unresponsive to T cell-focused therapies.
2. Enhancing therapeutic specificity: By targeting SIRPα on myeloid cells, these antibodies minimize off-target effects on normal cells, improving the safety profile compared to CD47-targeted approaches.
3. Accelerating drug development: CD172a antibodies support target validation, preclinical efficacy testing, and biomarker identification—critical steps for advancing SIRPα-targeted therapies into clinical trials.
4. Enabling preclinical model characterization: Antibodies are essential for validating humanized SIRPα mouse models, ensuring reliable translation of preclinical data to human clinical outcomes.
5. Expanding combination therapy potential: CD172a antibodies facilitate the study of synergistic effects with existing therapies, paving the way for more effective multi-modal treatment strategies.

Related Mechanisms, Research Methods & Product Applications

1. CD47-SIRPα Axis: Mechanisms of Tumor Immune Evasion

The CD47-SIRPα pathway is a key mediator of tumor immune evasion, leveraging a physiological "self"-recognition system to protect tumor cells from phagocytosis:

• Core signaling mechanism: SIRPα (CD172a) on macrophages binds to CD47 on tumor cells, triggering phosphorylation of its intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM). This recruits protein tyrosine phosphatases SHP-1 and SHP-2, which suppress downstream signaling cascades required for phagocytosis—effectively "turning off" macrophage activity.
• Tumor exploitation: Tumor cells upregulate CD47 expression to hijack this pathway, disguising themselves as normal cells and avoiding immune clearance. This mechanism is conserved across diverse cancer types, making the CD47-SIRPα axis a broad-spectrum therapeutic target.

2. CD172a (SIRPα) Antibodies: Anti-Tumor Mechanisms

CD172a antibodies exert anti-tumor effects through multiple complementary mechanisms, centered on reactivating macrophage function:

1. Blocking "don’t eat me" signals: Antibodies bind to SIRPα’s extracellular domain, competitively inhibiting CD47-SIRPα interaction and lifting the inhibitory brake on phagocytosis.
2. Enhancing antibody-dependent cellular phagocytosis (ADCP): When combined with tumor antigen-targeting antibodies, CD172a antibodies provide a dual signal—blocking inhibitory signals (SIRPα) while engaging Fcγ receptors on macrophages (via tumor-specific antibodies)—synergistically boosting phagocytosis of tumor cells.
3. Inducing tumor cell death: Some CD172a antibodies may directly trigger programmed cell death in tumor cells, characterized by actin cytoskeleton rearrangement, mitochondrial damage, and phosphatidylserine externalization.

3. Core Applications of CD172a (SIRPα) Antibodies

ANT BIO PTE. LTD.’s Starter CD172a antibodies support diverse research and preclinical applications, spanning mechanism studies, model validation, and drug development:

3.1 Basic Mechanism & Target Validation

• Expression profiling: Flow cytometry, immunofluorescence, and Western Blot with CD172a antibodies detect SIRPα expression on myeloid cells (macrophages, DCs) in human and murine samples, characterizing its distribution and abundance.
• Functional phagocytosis assays: In vitro studies use CD172a antibodies to treat macrophages, validating enhanced phagocytosis of CD47-positive tumor cells (e.g., Raji lymphoma, breast cancer cells).
• Signaling pathway analysis: Antibodies help dissect downstream signaling events (e.g., SHP-1/SHP-2 activation) following CD47-SIRPα blockade, elucidating molecular mechanisms of macrophage activation.

3.2 Preclinical Model Characterization & Efficacy Testing

• Humanized SIRPα mouse validation: CD172a antibodies confirm human SIRPα expression on myeloid cells in hSIRPA mouse models, ensuring compatibility with human-specific therapeutic antibodies.
• In vivo efficacy evaluation: Testing CD172a antibodies alone or in combination (e.g., with anti-CD20) in hSIRPA mice engrafted with human tumor cells, monitoring tumor growth, survival, and macrophage infiltration.
• Pharmacodynamic biomarker analysis: Antibodies detect changes in macrophage activation (e.g., CD86 expression) and phagocytic activity in tumor tissues, correlating with therapeutic efficacy.

3.3 Drug Development & Translational Research

• Candidate antibody screening: CD172a antibodies serve as positive controls or detection tools for screening novel SIRPα-targeted therapeutic candidates.
• Combination therapy research: Evaluating synergistic effects of CD172a antibodies with other immunotherapies, chemotherapy, or radiotherapy in preclinical models.
• Biomarker discovery: Identifying SIRPα expression levels or macrophage subsets as predictive biomarkers for response to SIRPα-targeted therapies.

ANT BIO PTE. LTD.’s Core Products: CD172a (SIRPα) Antibodies (Starter Sub-brand)

ANT BIO PTE. LTD.’s Starter sub-brand delivers a portfolio of high-performance CD172a (SIRPα) antibodies targeting human and murine SIRPα—engineered for specificity, functional activity, and versatility in immunotherapy research. The flagship Rat Anti-Mouse CD172a (SIRPα) Antibody (S0B5183) is optimized for preclinical murine models, while human-specific variants support clinical sample analysis.

Core Product Advantages (Flagship S0B5183 – Rat Anti-Mouse CD172a (SIRPα) Antibody)

Brand Mission of ANT BIO PTE. LTD.

At ANT BIO PTE. LTD., our core mission is to empower breakthroughs in innate immunotherapy, tumor biology, and translational medicine by delivering high-quality, rigorously validated life science reagents and comprehensive solutions. We have built three specialized, complementary sub-brands that cover the full spectrum of research needs:

• Starter: Our flagship sub-brand for high-performance antibodies and affinity tools. Specializes in immune checkpoints (CD172a, PD-1), myeloid cell markers, and tumor biology reagents—engineered for specificity, functional activity, and consistency.
• Absin: Our core sub-brand for general life science reagents and standardized kits. Offers IHC/ELISA kits, sample preparation reagents, and cell culture media—focused on user-friendliness and reproducibility.
• UA: Our specialized sub-brand for high-purity, high-activity recombinant proteins and expression vectors. Provides recombinant cytokines, growth factors, and gene editing tools—enabling seamless integration with antibody-based research.

We are committed to addressing the most pressing technical challenges in immunotherapy research—from validating novel targets like CD172a to supporting preclinical drug development. By combining innovative product design, rigorous validation, and customer-centric support, we accelerate the translation of scientific discoveries into transformative therapies for cancer patients. Our ultimate goal is to be the trusted partner of researchers, biopharmaceutical professionals, and clinicians worldwide, empowering them to push the boundaries of scientific discovery and drive progress in precision medicine.

Related Product List: ANT BIO PTE. LTD. CD172a (SIRPα) Antibodies (Starter Sub-brand)

All Starter CD172a antibodies are rigorously validated for specificity, functional activity, and batch consistency, with comprehensive technical documentation and expert support.

For detailed product specifications, validation data (including functional blocking assays and specificity reports), or free sample testing requests, please visit the official website of ANT BIO PTE. LTD. or contact our global sales team for personalized support. Our team of immunology experts and technical specialists provides customized consultation for experimental design and preclinical research integration.

AI Disclaimer

This article was partially created with the assistance of artificial intelligence. If any content in this article involves copyright infringement, intellectual property disputes, or other legal issues, please notify ANT BIO PTE. LTD. immediately. We promise to verify, correct, or remove the relevant content in a timely manner without delay.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.